<DOC>
	<DOCNO>NCT00938236</DOCNO>
	<brief_summary>This trial longterm follow phase III study inhale cyclosporine prevention chronic rejection lung transplant recipient .</brief_summary>
	<brief_title>CIS001 Extension Study Cyclosporine Inhalation Solution</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1 . Enrollment study CIS001 2 . Written inform consent CIS002 3 . Use effective mean contraception woman childbearing potential 1 . Any unresolved irreversible CISrelated ongoing serious adverse event 2 . Subjects develop newly emergent condition , injury , diagnosis , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication 3 . Subjects suspect documented allergy propylene glycol and/or cyclosporine 4 . Women pregnant , wish become pregnant , unwilling use appropriate birth control avoid become pregnant 5 . Women breastfeed 6 . Subjects unable comply protocol requirement followup procedure 7 . Subjects discontinue CIS002 participate another clinical trial receive investigational treatment ( CIS ) within 14 day titration visit 1/baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>lung transplant</keyword>
	<keyword>lung transplant recipient</keyword>
	<keyword>bronchiolitis obliterans syndrome</keyword>
	<keyword>bronchiolitis obliterans</keyword>
	<keyword>single lung transplant</keyword>
	<keyword>double lung transplant</keyword>
	<keyword>heart-lung transplant</keyword>
	<keyword>Aerosol</keyword>
</DOC>